Zhaohui Su, VP, Strategic Consulting at Veristat, shared a post on LinkedIn:
“The 2025 Scientific Report from Friends of Cancer Research serves as an excellent resource for stakeholders in drug development, regulatory policy, and advocacy. It offers insights, evidence-based strategies, and collaborative solutions aimed at advancing oncology drug development for patients. This report outlines four essential pillars:
- Modernizing Trial Designs with an Emphasis on Patient Centricity: Modernized, flexible trial designs can speed cancer drug development while maintaining patient centricity, access, and scientific rigor.
- AI-Driven Diagnostics: The application of machine learning to standardize biomarkers and AI-enabled imaging, such as the ai.RECIST project, enhancing the objectivity and efficiency of tumor assessments.
- Early Endpoints: The validation of novel markers like ctDNA, which can predict clinical outcomes significantly earlier than traditional Overall Survival (OS) data.
- Expanding Access: The creation of flexible manufacturing and regulatory pathways for Cell and Gene Therapies, ensuring that personalized cures are not hindered by outdated logistics.
Bringing a novel therapeutic to market requires a team that understands the intersection of science and data. Veristat offers flexible, end-to-end solutions, from strategic consulting on adaptive designs to full-service clinical trial execution, to help accelerate your path to approval.
Learn how we can support your next program.”
Other articles featuring Zhaohui Su on OncoDaily.